Document text
Centers for Disease Control and Prevention
National Center for Immunization and Respiratory Diseases
Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation
use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.
COVID- 19–Associated Hospitalizations among
Adults — COVID- NET, 2023 –2024
Advisory Committee on Immunization Practices (ACIP)
February 28, 2024
Christopher A. Taylor, PhD
RESP- NET Hospitalization Surveillance Team
Surveillance and Prevention Branch
Coronavirus and Other Respiratory Viruses Division
RESP -NET: COVID -NET, RSV -NET, FluSurv -NET
>300 acute -care hospitals
98 counties in 13 states
In 9 of 10 HHS regions
~10% of U.S. population
Positive SARS-CoV -2 within 14 days of or
during hospitalization
Screening or clinician-driven testing
Clinical data: representative sample of
COVID -NET patientsCOVID -NET: A RESP -NET population -based hospitalization
surveillance platform
Epidemiology of COVID -19–associated
hospitalizations among adults
Weekly Population -Based Rates of COVID -19-Associated
Hospitalizations — COVID -NET, March 2020– January 2024
020406080100120140
3/7/2020
5/7/2020
7/7/2020
9/7/2020
11/7/2020
1/7/2021
3/7/2021
5/7/2021
7/7/2021
9/7/2021
11/7/2021
1/7/2022
3/7/2022
5/7/2022
7/7/2022
9/7/2022
11/7/2022
1/7/2023
3/7/2023
5/7/2023
7/7/2023
9/7/2023
11/7/2023
1/7/2024Rate per 100,000 population
Week Ending DateMarch 1, 2020 –January 27, 2024
18–49 years 50–64 years 65–74 years ≥75 years020406080100120140
10/7/2023 11/7/2023 12/7/2023 1/7/2024Rate per 100,000 population
Week Ending DateOctober 2023 –January 2024
Gray boxes indicate potential reporting delays. Interpretation of trends should be excluded from these weeks. Rates highest in adults ages ≥75 years.
Percent of Weekly Hospitalizations by Age Group —
COVID -NET, March 2020– January 2024
0%10%20%30%40%50%60%70%80%90%100%
3/7/2020
4/11/2020
5/16/2020
6/20/2020
7/25/2020
8/29/2020
10/3/2020
11/7/2020
12/12/2020
1/16/2021
2/20/2021
3/27/2021
5/1/2021
6/5/2021
7/10/2021
8/14/2021
9/18/2021
10/23/2021
11/27/2021
1/1/20222/5/2022
3/12/20224/16/20225/21/20226/25/2022
7/30/2022
9/3/2022
10/8/2022
11/12/202212/17/2022
1/21/20232/25/2023
4/1/2023
5/6/2023
6/10/2023
7/15/2023
8/19/2023
9/23/2023
10/28/2023
12/2/2023
1/6/2024Percent of COVID -19-associated hospitalizations
Week ending date
≤17 years 18–49 years 50–64 years 65–74 years 75–84 years ≥85 years≥65: 67% of COVID -19
hospitalizations October
2023– January 2024
<65: 33% of COVID -19
hospitalizations October 2023– January 2024≥75: 46% of COVID -19
hospitalizations October 2023–January 2024
05101520253035
October
2022November
2022December
2022January
2023February
2023March 2023 April 2023 May 2023 June 2023 July 2023 August 2023 September
2023October
2023November
2023Weighted % of COVID -19-Associated HospitalizationsAmong adults ages ≥75 years during October 2022–November 2023, 25% of
COVID -19-associated hospitalizations were residents of a long -term care
facility.
01234567
18–49 years 50–64 years 65–74 years ≥75 years All AdultsWeighted % of Hospitalizations1.4%,
N=383.3%,
N=555.5%,
N=70
4.0%,
N=853.8%,
N=238Percent of COVID -19-Associated Hospitalizations Resulting in In -Hospital
Death, by Age Group — COVID -NET, October 2022 –November 2023
An examination of death certificate data from March 2020 –April 2022 found that among all deaths in adults with COVID -19-associat ed hospitalization,
67% occurred in -hospital and 33% occurred ≤30 days post -discharge. Among adults ages ≥65
years who died in -hospital,
28% were residents of
long -term care facilities.
Percent of COVID-19 -Associated Hospitalizations with
Immunocompromising Conditions*, by Age Group —
COVID -NET, October 2022 –November 2023
121921
1316
051015202530
18–49 years 50–64 years 65–74 years ≥75 years All AdultsWeighted % of hospitalizations
* Immunocompromising conditions include AIDS or CD4 count<200, complement deficiency, graft vs host disease, HIV, immunoglobu lin deficiency, receipt of immunosuppressive therapy,
leukemia, lymphoma, solid organ malignancy, bone marrow transplant, metastatic cancer, multiple myeloma, steroid therapy, solid organ transplant, and other conditions adjudicated by
RESP -NET physicians to be immunocompromising in nature.
Percent of COVID -19-Associated Hospitalizations with Immunocompromising
Conditions among All Adults Ages ≥18 Years, Overall and by Outcome — COVID -NET,
October 2022– November 2023
16% 17%28%
0%10%20%30%40%50%60%70%80%90%100%
All Hospitalizations ICU Admissions In-Hospital DeathsWeighted % of Hospitalizations
Immunocompromised Not Immunocompromised
* Immunocompromising conditions include AIDS or CD4 count<200, complement deficiency, graft vs host disease, HIV, immunoglobu lin deficiency, receipt of immunosuppressive therapy,
leukemia, lymphoma, solid organ malignancy, bone marrow transplant, metastatic cancer, multiple myeloma, steroid therapy, solid organ transplant, and other conditions adjudicated by
RESP -NET physicians to be immunocompromising in nature.N=75
(of 251
deaths)N=206
(of 1,035 ICU
admissions)
Percent of Hospitalizations among Adults Ages ≥18 Years with Underlying Medical Conditions
by Age Group, with Top 4 Conditions Highlighted — COVID -NET, October 2022 –November 2023
Condition 18–49 yrs 50–64 yrs 65–74 yrs ≥75 yrs
Chronic lung disease 23 36 45 34
Asthma 19 17 14 9
COPD/Bronchitis 3 16 24 16
Cardiovascular disease 20 47 61 67
CAD/CABG/MI 5 17 27 27
CHF/Cardiomyopathy 6 18 25 25
Stroke/TIA 3 13 15 20
Diabetes 21 40 44 37
Immunocompromising condition 12 19 21 13
Neurologic condition 18 26 30 42
Dementia 0 1 6 29
Renal Disease 8 21 24 31
Obesity 42 43 39 23
COVID -19 Vaccination Status by Age Group among Adults Ages ≥18 Years
Hospitalized with COVID -19 — COVID -NET, October –November 2023 (Preliminary)
No record of bivalent or updated monovalent dose : No recorded doses of COVID -19 bivalent or updated 2023 -2024monovalent dose. Bivalent booster, but no updated monovalent doses :
Received COVID -19 bivalent booster vaccination but no record of receiving updated 2023 -2024 monovalent booster dose. Updated monovalent dose: Received updated 2023- 2024 monovalent
dose Persons with unknown vaccination status are excluded 87
73677012
2528252 2 5 4
0%10%20%30%40%50%60%70%80%90%100%
18–49 years 50–64 years ≥65 years All Adults, ≥18 yearsWeighted percent of hospitalizations
No record of bivalent or updated monovalent dose Bivalent booster, but no updated monovalent dose Updated monovalent dose
Coronavirus and Other Respiratory
Viruses Division
Fiona Havers
Huong Pham
Kadam Patel
Michael Whitaker
RESP -NET Site investigators and staffAcknowledgements
For more information, contact CDC
1-800- CDC- INFO (232 -4636)
TTY: 1 -888 -232-6348 www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official
position of the Centers for Disease Control and Prevention.
Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation
use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.